Premium
Subchronic administration of riparin III induces antidepressive‐like effects and increases BDNF levels in the mouse hippocampus
Author(s) -
Vasconcelos Auriana S.,
Oliveira Iris C.M.,
Vidal Laura T.M.,
Rodrigues Gabriel C.,
Gutierrez Stanley J.C.,
BarbosaFilho José M.,
Vasconcelos Silvânia M.M.,
França Fonteles Marta M.,
Gaspar Danielle M.,
Sousa Francisca C.F.
Publication year - 2015
Publication title -
fundamental and clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.655
H-Index - 73
eISSN - 1472-8206
pISSN - 0767-3981
DOI - 10.1111/fcp.12120
Subject(s) - tail suspension test , corticosterone , behavioural despair test , hippocampus , hippocampal formation , saline , anxiolytic , analysis of variance , endocrinology , medicine , chemistry , antidepressant , brain derived neurotrophic factor , pharmacology , neurotrophic factors , receptor , hormone
Riparin III (Rip III ) is an alcamide isolated from A niba riparia that has presented effects of antidepressant and anxiolytic activities in acute stress behavioral models. The trial's goal was to investigate the activity of R ip III in mice exposed to corticosterone‐induced chronic depression model. Swiss female mice, 22–25 g, were distributed in following experimental groups: control group (vehicle1: saline containing 0.1% dimethyl sulfoxide and 0.1% T ween‐80, SC + vehicle 2: distilled water emulsified with 2% T ween‐80, PO ); stressed group (corticosterone, 20 mg/kg, SC , + vehicle 2, orally); Rip III group (50 mg/kg, orally); and fluvoxamine ( F lu) group (50 mg/kg, orally). The mice were exposed to the behavioral tests, and posteriorly, Brain‐derived neurotrophic factor protein levels were assessed in hippocampal samples. Statistical analysis of the data was performed by one‐way anova , followed by N ewman– K euls test. Both administrations of R ip III and F lu significantly reduced the immobility time in tail suspension and forced swimming tests after 21 days without affecting locomotor function. There was also an increase in BDNF protein levels in the mice hippocampus. These findings further support the hypothesis that R ip III could be a new pharmacological target for the treatment of mood disorders.